Literature DB >> 10753826

Structure of the activation domain of the GM-CSF/IL-3/IL-5 receptor common beta-chain bound to an antagonist.

J Rossjohn1, W J McKinstry, J M Woodcock, B J McClure, T R Hercus, M W Parker, A F Lopez, C J Bagley.   

Abstract

Heterodimeric cytokine receptors generally consist of a major cytokine-binding subunit and a signaling subunit. The latter can transduce signals by more than 1 cytokine, as exemplified by the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and IL-6 receptor systems. However, often the signaling subunits in isolation are unable to bind cytokines, a fact that has made it more difficult to obtain structural definition of their ligand-binding sites. This report details the crystal structure of the ligand-binding domain of the GM-CSF/IL-3/IL-5 receptor beta-chain (beta(c)) signaling subunit in complex with the Fab fragment of the antagonistic monoclonal antibody, BION-1. This is the first single antagonist of all 3 known eosinophil-producing cytokines, and it is therefore capable of regulating eosinophil-related diseases such as asthma. The structure reveals a fibronectin type III domain, and the antagonist-binding site involves major contributions from the loop between the B and C strands and overlaps the cytokine-binding site. Furthermore, tyrosine(421) (Tyr(421)), a key residue involved in receptor activation, lies in the neighboring loop between the F and G strands, although it is not immediately adjacent to the cytokine-binding residues in the B-C loop. Interestingly, functional experiments using receptors mutated across these loops demonstrate that they are cooperatively involved in full receptor activation. The experiments, however, reveal subtle differences between the B-C loop and Tyr(421), which is suggestive of distinct functional roles. The elucidation of the structure of the ligand-binding domain of beta(c) also suggests how different cytokines recognize a single receptor subunit, which may have implications for homologous receptor systems. (Blood. 2000;95:2491-2498)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10753826

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  An improved resolution structure of the human beta common receptor involved in IL-3, IL-5 and GM-CSF signalling which gives better definition of the high-affinity binding epitope.

Authors:  P D Carr; F Conlan; S Ford; D L Ollis; I G Young
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-05-31

Review 2.  The route to pathologies in chronic inflammatory diseases characterized by T helper type 2 immune cells.

Authors:  K Jovanovic; M Siebeck; R Gropp
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

3.  Overexpression of transmembrane protein 102 implicates poor prognosis and chemoresistance in epithelial ovarian carcinoma patients.

Authors:  Yi-Jou Tai; Cheng-Miao Ou; Ying-Cheng Chiang; Chi-Fang Chang; Chi-An Chen; Wen-Fang Cheng
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

4.  Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.

Authors:  Michael Brines; Giovanni Grasso; Fabio Fiordaliso; Alessandra Sfacteria; Pietro Ghezzi; Maddalena Fratelli; Roberto Latini; Qiao-Wen Xie; John Smart; Chiao-Ju Su-Rick; Eileen Pobre; Deborah Diaz; Daniel Gomez; Carla Hand; Thomas Coleman; Anthony Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-29       Impact factor: 11.205

5.  The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis.

Authors:  Craig S Clements; Hugh H Reid; Travis Beddoe; Fleur E Tynan; Matthew A Perugini; Terrance G Johns; Claude C A Bernard; Jamie Rossjohn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

Review 6.  The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease.

Authors:  Timothy R Hercus; Daniel Thomas; Mark A Guthridge; Paul G Ekert; Jack King-Scott; Michael W Parker; Angel F Lopez
Journal:  Blood       Date:  2009-05-12       Impact factor: 22.113

7.  A Miniature Protein Stabilized by a Cation-π Interaction Network.

Authors:  Timothy W Craven; Min-Kyu Cho; Nathaniel J Traaseth; Richard Bonneau; Kent Kirshenbaum
Journal:  J Am Chem Soc       Date:  2016-01-26       Impact factor: 15.419

Review 8.  Clinical usefulness of mepolizumab in severe eosinophilic asthma.

Authors:  Francesco Menzella; Mirco Lusuardi; Gloria Montanari; Carla Galeone; Nicola Facciolongo; Luigi Zucchi
Journal:  Ther Clin Risk Manag       Date:  2016-06-08       Impact factor: 2.423

Review 9.  Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.

Authors:  Corrado Pelaia; Alessandro Vatrella; Maria Teresa Busceti; Luca Gallelli; Rosa Terracciano; Rocco Savino; Girolamo Pelaia
Journal:  Drug Des Devel Ther       Date:  2017-10-30       Impact factor: 4.162

Review 10.  Role of biologics in severe eosinophilic asthma - focus on reslizumab.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Maria Teresa Busceti; Luca Gallelli; Mariaimmacolata Preianò; Nicola Lombardo; Rosa Terracciano; Rosario Maselli
Journal:  Ther Clin Risk Manag       Date:  2016-07-01       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.